These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33748950)

  • 1. Cerebral aspergillosis in a patient on ibrutinib therapy.
    Creuzet E; Nourrisson C; Chaleteix C; Poirier P; Moniot M
    Br J Haematol; 2021 Jun; 193(6):1025. PubMed ID: 33748950
    [No Abstract]   [Full Text] [Related]  

  • 2. [Aspergillus spondylodiscitis in a patient treated with ibrutinib].
    Petitdemange A; Martin A; Ruch Y; Chatron E; Karol A; Hansmann Y
    Med Mal Infect; 2020 May; 50(3):296-297. PubMed ID: 31722863
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
    Molica S; Baumann T; Giannarelli D
    Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
    [No Abstract]   [Full Text] [Related]  

  • 4. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
    Molica S; Giannarelli D; Baumann T; Montserrat E
    Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067
    [No Abstract]   [Full Text] [Related]  

  • 5. An oral drug for chronic lymphocytic leukemia.
    Koehler A
    JAAPA; 2020 Feb; 33(2):51-53. PubMed ID: 31990837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
    Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
    Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
    [No Abstract]   [Full Text] [Related]  

  • 7. Ibrutinib Treatment and EGFR-mutant Lung Adenocarcinoma.
    Shulman K; Kazarin O; Tannous E; Sofer O
    Isr Med Assoc J; 2021 Jun; 23(6):385-386. PubMed ID: 34155856
    [No Abstract]   [Full Text] [Related]  

  • 8. Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Ozbagcivan O; Akarsu S; Nazli EC; Lebe B; Fetil E
    Ann Hematol; 2021 Jan; 100(1):293-294. PubMed ID: 32221651
    [No Abstract]   [Full Text] [Related]  

  • 9. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cerebral aspergillosis: presentation of a case].
    Marsella M; Benvenuti L; Gagliardi R; Gargani G
    Arch De Vecchi Anat Patol; 1983 Jul; 65(2-3):169-74. PubMed ID: 6391387
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
    Pleyer C; Tian X; Rampertaap S; Mu R; Soto S; Superata J; Gaglione E; Sun C; Lotter J; Stetler-Stevenson M; Yuan CM; Maric I; Pittaluga S; Rosenzweig S; Fleisher T; Wiestner A; Ahn IE
    Am J Hematol; 2020 Nov; 95(11):E310-E313. PubMed ID: 32808680
    [No Abstract]   [Full Text] [Related]  

  • 12. Non-Aspergillus invasive mould infections in patients treated with ibrutinib.
    Anastasopoulou A; DiPippo AJ; Kontoyiannis DP
    Mycoses; 2020 Aug; 63(8):787-793. PubMed ID: 32458510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
    İskender G; İskender D; Ertek M
    Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
    [No Abstract]   [Full Text] [Related]  

  • 14. Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib.
    Brener ZZ; Brener H; Losev A
    J Oncol Pharm Pract; 2020 Oct; 26(7):1735-1737. PubMed ID: 32054411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib-associated necrotic nasal lesion and pulmonary infiltrates.
    Saling C; Feller F; Vikram HR
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33468501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
    Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
    Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
    [No Abstract]   [Full Text] [Related]  

  • 17. Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?
    Gaye E; Le Bot A; Talarmin JP; Le Calloch R; Belaz S; Dupont M; Tattevin P
    Med Mal Infect; 2018 Jun; 48(4):294-297. PubMed ID: 29402474
    [No Abstract]   [Full Text] [Related]  

  • 18. Ibrutinib-Induced Skin Rash.
    Kirar S; Gogia A; Gupta R; Mallick S
    Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
    [No Abstract]   [Full Text] [Related]  

  • 19. Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients.
    Cassin R; Visentin A; Giannarelli D; Noto A; Mauro FR; Baldini L; Trentin L; Reda G
    Hematol Oncol; 2021 Feb; 39(1):141-144. PubMed ID: 33034902
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.
    Aarup K; Rotbain EC; Enggaard L; Pedersen RS; Bergmann OJ; Thomsen RH; Frederiksen M; Frederiksen H; Nielsen T; Christiansen I; Andersen MA; Niemann CU
    Eur J Haematol; 2020 Nov; 105(5):646-654. PubMed ID: 32736410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.